Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)
- Conditions
- Small Cell Lung Cancer
- Interventions
- Registration Number
- NCT03061812
- Lead Sponsor
- AbbVie
- Brief Summary
The purpose of this randomized, open-label, 2-arm, phase 3 study is to assess the efficacy, safety and tolerability of rovalpituzumab tesirine versus topotecan in participants with advanced or metastatic SCLC with high levels of DLL3, who have first disease progression during or following front-line platinum-based chemotherapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 444
- Participant must have histologically or cytologically confirmed advanced or metastatic Small Cell Lung Cancer (SCLC) with documented first disease progression during or following front-line platinum-based systemic regimen
- Tumor must have high Delta-like protein 3 (DLL3) expression defined as having ≥ 75% tumor cells staining positive according to the VENTANA DLL3 (SP347) IHC Assay.
- Participant must have measurable disease, as defined per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Participant must have recovery to Grade 0 or 1 of any clinically significant toxicity (excluding alopecia) prior to initiation of study drug administration.
- Participant has a documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms consistent with New York Heart Association Class (NYHA) III - IV within 6 months prior to their first dose of study drug.
- Participant has known leptomeningeal metastases.
- Participant has received more than one prior systemic therapy regimen for SCLC.
- Participant had a serious infection within 2 weeks prior to randomization, including any Grade 3 or higher viral, bacterial, or fungal infection.
- Participant has a history of active malignancies other than SCLC within the past 2 years prior to study entry, with the exception of in situ cancer which was curatively treated.
- Participant had prior exposure to topotecan, irinotecan or any other topoisomerase I inhibitors.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Rovalpituzumab tesirine Dexamethasone Rovalpituzumab tesirine IV administration (dosing based on actual body weight) on Day 1 of a 42-day cycle for 2 cycles, with up to 2 additional cycles permitted. Dexamethasone coadministered orally (PO) twice daily at a dose of 8 mg on Day -1, Day 1, and Day 2 of each 42-day cycle in which rovalpituzumab tesirine is administered. Topotecan Topotecan Topotecan given as an intravenous (IV) infusion over 30 minutes at a dose of 1.5 mg/m\^2 on Days 1 to 5 of each 21-day cycle. Rovalpituzumab tesirine Rovalpituzumab tesirine Rovalpituzumab tesirine IV administration (dosing based on actual body weight) on Day 1 of a 42-day cycle for 2 cycles, with up to 2 additional cycles permitted. Dexamethasone coadministered orally (PO) twice daily at a dose of 8 mg on Day -1, Day 1, and Day 2 of each 42-day cycle in which rovalpituzumab tesirine is administered.
- Primary Outcome Measures
Name Time Method Overall Survival (OS) From randomization until the end of study; median time on follow-up was 20 and 20.6 months for the topotecan and rovalpituzumab tesirine arms, respectively. OS is defined as the time from the date of randomization to the date of death from any cause. Participants were censored at the last date they were documented alive. After the End of treatment, survival information was collected at approximately 6-week intervals (or as requested by sponsor to support data analysis) continuing until the endpoint of death, the participant became lost to follow-up, AbbVie terminated the study, or until 12 February 2020. Calculated using the Kaplan-Meier product-limit method.
- Secondary Outcome Measures
Name Time Method Progression Free Survival (PFS) From randomization until the end of study; median time on follow-up was 20 and 20.6 months for the topotecan and rovalpituzumab tesirine arms, respectively. PFS is defined as the number of months from the date of randomization until the date of first progression or the date of a participant's death, whichever occurs first. If a participant neither experienced disease progression nor died, then the participant's data were censored at the last date of radiographic assessment that they were documented to be progression free. Calculated using the Kaplan-Meier product-limit method.
Radiographic tumor assessments for response were conducted by CT scanning according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. Progressive Disease (PD) was defined as at least a 20% increase in the size of target lesions and an absolute increase of at least 5 mm taking as reference the smallest lesion size recorded since the treatment started (baseline or after), or the appearance of one or more new lesions.Objective Response Rate (ORR) Radiographic tumor assessments were conducted at baseline, every 6 weeks for 30 weeks, then every 9 weeks until progression or death; median time on follow-up was 20 and 20.6 months for the topotecan and rovalpituzumab tesirine arms, respectively. ORR is defined as the percentage of participants whose best overall response is either complete response (CR) or partial response (PR) according to RECIST version 1.1. Radiographic tumor assessments for response were conducted by CT scanning, and assessed from the date of randomization until disease progression or death, whichever came first. Any participant who did not meet CR or PR, including those who did not have post-baseline radiological assessments were considered non-responders.
CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.Clinical Benefit Rate (CBR) Radiographic tumor assessments were conducted at baseline, every 6 weeks for 30 weeks, then every 9 weeks until progression or death; median time on follow-up was 20 and 20.6 months for the topotecan and rovalpituzumab tesirine arms, respectively. CBR is defined as percentage of participants whose best overall response is CR, PR, or stable disease (SD) according to RECIST version 1.1. Radiographic tumor assessments for response were conducted by CT scanning, and assessed from the date of randomization until disease progression or death, whichever came first. Any participant who did not meet CR, PR, or SD, including those who did not have post-baseline radiological assessments were considered as experiencing no clinical benefit.
CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.Change From Baseline of the Physical Functioning Scale Score in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 15-Palliative Care (EORTC QLQ-C15-PAL) at Week 7 Baseline, Week 7 The EORTC QLQ-C15-PAL is an abbreviated 15-item version of the EORTC core quality of life questionnaire (EORTC QLQ-C30) developed for use in palliative care. The score of 'physical functioning scale' score ranges from 0 (very poor) to 100 (excellent).
Duration of Objective Response (DOR) Radiographic tumor assessments were conducted at baseline, every 6 weeks for 30 weeks, then every 9 weeks until progression or death; median time on follow-up was 20 and 20.6 months for the topotecan and rovalpituzumab tesirine arms, respectively. DOR is defined as the time between the date of first response (CR or PR, whichever is recorded first) to the date of the first documented tumor progression (per RECIST version 1.1) or death due to any cause, whichever comes first. Radiographic tumor assessments for response were conducted by CT scanning, and assessed from the date of randomization until disease progression or death, whichever came first. Any participant who did not meet CR or PR, including those who did not have post-baseline radiological assessments were considered non-responders.
CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Trial Locations
- Locations (195)
Georgia Cancer Center /ID# 160206
🇺🇸Atlanta, Georgia, United States
Cedars-Sinai Medical Center /ID# 157102
🇺🇸Beverly Hills, California, United States
Mitchell Cancer Institute /ID# 158151
🇺🇸Mobile, Alabama, United States
Moore UC San Diego Cancer Center /ID# 156965
🇺🇸La Jolla, California, United States
Highlands Oncology Group /ID# 155902
🇺🇸Springdale, Arkansas, United States
UT Southwestern Medical Center /ID# 158150
🇺🇸Dallas, Texas, United States
Carti /Id# 156982
🇺🇸Little Rock, Arkansas, United States
Icri /Id# 157090
🇺🇸Whittier, California, United States
St George Hospital /ID# 158855
🇦🇺Kogarah, New South Wales, Australia
Nebraska Hematology Oncology /ID# 155900
🇺🇸Lincoln, Nebraska, United States
Asklepios Fachkliniken M. Gaut /ID# 158791
🇩🇪Gauting, Germany
Petz Aladar Megyei Oktato Korh /ID# 158978
🇭🇺Gyor, Hungary
Assis.Publique-Hopital Nord /ID# 160554
🇫🇷Marseille, Provence-Alpes-Cote-d Azur, France
Fundacao Pio XII - Hospital de Cancer de Barretos /ID# 159017
🇧🇷Barretos, Sao Paulo, Brazil
Nemocnice Na Plesi s.r.o. /ID# 161190
🇨🇿Nová Ves pod Pleší, Pribram, Czechia
Los Angeles Hematology Oncolog /ID# 155879
🇺🇸Los Angeles, California, United States
Centre Leon Berard /ID# 160561
🇫🇷Lyon CEDEX 08, Rhone, France
NorthShore University HealthSystem - Evanston Hospital /ID# 157054
🇺🇸Evanston, Illinois, United States
University of Vermont Medical Center /ID# 162317
🇺🇸Burlington, Vermont, United States
Grand Hôpital de Charleroi /ID# 158748
🇧🇪Charleroi, Hainaut, Belgium
CHU de Liege Sart Tilman /ID# 158753
🇧🇪Liege, Belgium
UMHAT Tsaritsa Joanna - ISUL /ID# 159641
🇧🇬Sofia, Bulgaria
Istituto Europeo di Oncologia /ID# 158942
🇮🇹Milan, Italy
Ingalls Memorial Hosp /ID# 155871
🇺🇸Harvey, Illinois, United States
Goshen Center for Cancer Care /ID# 155946
🇺🇸Goshen, Indiana, United States
Christiana Care Health Service /ID# 158171
🇺🇸Newark, Delaware, United States
Nemocnice Rudolfa a Stefanie /ID# 159652
🇨🇿Benesov, Czechia
Ochsner Clinic Foundation /ID# 160807
🇺🇸Baton Rouge, Louisiana, United States
Klinik Loewenstein GmbH /ID# 159167
🇩🇪Löwenstein, Germany
State Institution Republican Scientific Practical Center of Oncology and Medica /ID# 159325
🇧🇾Lesnoy, Belarus
CHU Charleroi (Vesale) /ID# 159756
🇧🇪Montigny-le-tilleul, Belgium
Klinika za plucne bolesti Jordanovac /ID# 159502
🇭🇷Zagreb, Grad Zagreb, Croatia
Euromedica General Clinic /ID# 159161
🇬🇷Thessaloniki, Greece
Yokohama City University Hospital /ID# 165748
🇯🇵Yokohama-shi, Kanagawa, Japan
St. Luke's Mountain States Tumor Institute - Meridian /ID# 164550
🇺🇸Meridian, Idaho, United States
A.O.U. San Luigi Gonzaga /ID# 158945
🇮🇹Orbassano, Italy
Hospital Pontchaillou /ID# 160555
🇫🇷Rennes, France
Blacktown Hospital /ID# 158907
🇦🇺Blacktown, New South Wales, Australia
Sparrow Regional Cancer Center, Sparrow Health System /ID# 157021
🇺🇸Lansing, Michigan, United States
Nemocnice Horovice a.s. /ID# 161191
🇨🇿Horovice, Czechia
Hopital de Jolimont /ID# 159755
🇧🇪Haine Saint Paul, Belgium
UMHAT Sv. Ivan Rilski /ID# 159642
🇧🇬Sofia, Bulgaria
The Prince Charles Hospital /ID# 158897
🇦🇺Chermside, Queensland, Australia
Chonnam National University Hospital /ID# 159294
🇰🇷Gwangju, Jeonranamdo, Korea, Republic of
Ballarat Health Service /ID# 158904
🇦🇺Ballarat, Victoria, Australia
Krajska nemocnice Liberec a.s. /ID# 159653
🇨🇿Liberec, Czechia
University Hospital of Ioannin /ID# 159163
🇬🇷Ioannina, Greece
Matrai Gyogyintezet /ID# 158979
🇭🇺Matrahaza, Hungary
National Cancer Center Hospital East /ID# 165726
🇯🇵Kashiwa-shi, Chiba, Japan
Ataturk Gogus Hastaliklari ve /ID# 160056
🇹🇷Kecioren/ankara, Turkey
Hospital General Universitario Gregorio Maranon /ID# 159025
🇪🇸Madrid, Spain
Orszagos Koranyi Pulmonologiai Intezet /ID# 158967
🇭🇺Budapest, Hungary
Yonsei University Health System, Severance Hospital /ID# 159288
🇰🇷Seodaemun-gu, Seoul Teugbyeolsi, Korea, Republic of
Torokbalinti Tudogyogyintezet /ID# 207053
🇭🇺Budapest, Pest, Hungary
Hospital Santa Creu i Sant Pau /ID# 159028
🇪🇸Barcelona, Spain
Kansai Medical University Hospital /ID# 165055
🇯🇵Hirakata-shi, Osaka, Japan
Tokushima University Hospital /ID# 165812
🇯🇵Tokushima-shi, Tokushima, Japan
Hospital da Luz, SA /ID# 158996
🇵🇹Lisbon, Portugal
Sahlgrenska US Gbg /ID# 159534
🇸🇪Göteborg, Vastra Gotalands Lan, Sweden
Hospital Universitario HM Sanchinarro /ID# 159024
🇪🇸Madrid, Spain
Asan Medical Center /ID# 159290
🇰🇷Seoul, Korea, Republic of
Health Pharma Professional Research S.A de C.V /ID# 160020
🇲🇽Del. Benito Juárez, Mexico
Uppsala University Hospital /ID# 159050
🇸🇪Uppsala, Sweden
Dr. Suat Seren Gogus Has /ID# 159240
🇹🇷Izmir, Turkey
United Lincolnshire Hospitals /ID# 159579
🇬🇧Boston, United Kingdom
Universitair Medisch Centrum Groningen /ID# 158088
🇳🇱Groningen, Netherlands
Hospital Clinico Universitario de Valencia /ID# 159027
🇪🇸Valencia, Spain
CHA Bundang Medical center CHA University /ID# 204416
🇰🇷Seongnam si, Gyeonggido, Korea, Republic of
Dong-A University Hospital /ID# 159296
🇰🇷Busan, Busan Gwang Yeogsi, Korea, Republic of
Copernicus PL Sp. z o. o., WCO /ID# 160538
🇵🇱Gdansk, Poland
IPO Lisboa FG, EPE /ID# 158995
🇵🇹Lisboa, Portugal
S.C. Centrul de Oncologie Sf. Nectarie S.R.L. /ID# 160847
🇷🇴Craiova, Dolj, Romania
PMI Euromedservice /ID# 159311
🇷🇺Pushkin, Russian Federation
National Cancer Ctr Singapore /ID# 158803
🇸🇬Singapore, Singapore
Ege University Medical Faculty /ID# 159239
🇹🇷Izmir, Turkey
Royal Preston Hospital /ID# 159578
🇬🇧Preston, United Kingdom
National Cheng Kung University Hospital /ID# 158844
🇨🇳Tainan City, Tainan, Taiwan
Municipal institution /ID# 159867
🇺🇦Chernivtsi, Ukraine
Christie NHS Foundation Trust /ID# 159099
🇬🇧Manchester, United Kingdom
Regional Center of Oncology /ID# 159123
🇺🇦Kharkiv, Ukraine
Communal Nonprofit Enterprise "Central City Clinical Hospital" of Uzhhorod City /ID# 159868
🇺🇦Uzhhorod, Ukraine
Inonu Universitesi Turgut Ozal /ID# 159241
🇹🇷Battalgazi/malatya, Turkey
Tri-Service General Hospital /ID# 158985
🇨🇳Taipei City, Taipei, Taiwan
Guy's and St Thomas' NHS Found /ID# 159581
🇬🇧London, London, City Of, United Kingdom
Charing Cross Hospital /ID# 159582
🇬🇧London, United Kingdom
Clearview Cancer Institute /ID# 155873
🇺🇸Huntsville, Alabama, United States
Dana-Farber Cancer Institute /ID# 160210
🇺🇸Boston, Massachusetts, United States
UPMC Hillman Cancer Ctr /ID# 164403
🇺🇸Pittsburgh, Pennsylvania, United States
St Jude Hospital dba St Joseph /ID# 155899
🇺🇸Santa Rosa, California, United States
Gabrail Cancer Center Research /ID# 155920
🇺🇸Canton, Ohio, United States
University of Washington /ID# 162626
🇺🇸Seattle, Washington, United States
Medical Oncology Associates /ID# 156856
🇺🇸Spokane, Washington, United States
West Virginia Univ School Med /ID# 155872
🇺🇸Morgantown, West Virginia, United States
Mogilev Reg. Oncologic dispe /ID# 159326
🇧🇾Mogilev, Belarus
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 159666
🇧🇷Sao Jose Do Rio Preto, Sao Paulo, Brazil
Klinicki bolnicki centar Rijeka /ID# 159501
🇭🇷Rijeka, Primorsko-goranska Zupanija, Croatia
KH Martha-Maria Halle Dolau /ID# 158796
🇩🇪Halle (Saale), Sachsen-Anhalt, Germany
Lungen Clinic Grosshansdorf /ID# 158770
🇩🇪Grosshansdorf, Germany
Klinikum Kassel /ID# 158788
🇩🇪Kassel, Germany
General Hospital of Chest Diseases of Athens SOTIRIA /ID# 159165
🇬🇷Athens, Greece
Dup_Debreceni Egyetem Klinikai Központ /ID# 161209
🇭🇺Debrecen, Hungary
Veszprem Megyei Tuedoegyogyint /ID# 162607
🇭🇺Farkasgyepu, Hungary
Hokkaido Cancer Center /ID# 165237
🇯🇵Sapporo-shi, Hokkaido, Japan
Hyogo Cancer Center /ID# 165125
🇯🇵Akashi-shi, Hyogo, Japan
Kindai University Hospital /ID# 166394
🇯🇵Osaka-sayama-shi, Osaka, Japan
Duplicate_Showa University Hospital /ID# 165574
🇯🇵Shinagawa-ku, Tokyo, Japan
Kyungpook National University Chilgok Hospital /ID# 159292
🇰🇷Daegu, Seoul Teugbyeolsi, Korea, Republic of
Mrukmed. Lekarz Beata Madej Mruk i Partner /ID# 160537
🇵🇱Rzeszów, Podkarpackie, Poland
IPO Porto FG, EPE /ID# 158686
🇵🇹Porto, Portugal
National Medical Research Cntr /ID# 207436
🇷🇺Moscow, Moskovskaya Oblast, Russian Federation
LLC BioEq Ltd. /ID# 159310
🇷🇺St. Petersburg, Russian Federation
Klinicki centar Srbije /ID# 160024
🇷🇸Belgrade, Serbia
National University Hospital /ID# 158802
🇸🇬Singapore, Singapore
Institute For Pulmonary Diseas /ID# 158813
🇷🇸Sremska Kamenica, Serbia
CI Zaporizhzhia Regional Clinical Oncological Dispensary /ID# 159122
🇺🇦Zaporizhzhia, Zaporizka Oblast, Ukraine
PE PMC Acinus, Medical and Diagnostic Center /ID# 159125
🇺🇦Kropyvnytskyi, Ukraine
Jilin Cancer Hosptial /ID# 204059
🇨🇳Changchun, Jilin, China
Liga Norte Rio Grandense Cont. /ID# 159015
🇧🇷Natal, Rio Grande Do Norte, Brazil
Associação Hospital Beneficente São Vicente de Paulo - Hospital São Vicente de P /ID# 159668
🇧🇷Passo Fundo, Rio Grande Do Sul, Brazil
Herlev Hospital /ID# 158049
🇩🇰Herlev, Hovedstaden, Denmark
Rigshospitalet, Finsen Centre /ID# 158051
🇩🇰Copenhagen, Denmark
Odense Universitets Hospital /ID# 158050
🇩🇰Odense C, Syddanmark, Denmark
James Cook University Hospital /ID# 159583
🇬🇧Middlesborough, United Kingdom
Oregon Health and Science University /ID# 157055
🇺🇸Portland, Oregon, United States
Assistance Publique- Hopitaux /ID# 160552
🇫🇷Paris, France
AUSL 8 Arezzo Ospedale San Don /ID# 160967
🇮🇹Arezzo, Italy
Ospedale Santa Maria delle Cro /ID# 158940
🇮🇹Ravenna, Italy
IFO Istituto Nazionale Tumori /ID# 158941
🇮🇹Rome, Italy
Korea University Guro Hospital /ID# 159293
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Himeji Medical Center /ID# 165893
🇯🇵Himeji-shi, Hyogo, Japan
The Cancer Institute Hospital Of JFCR /ID# 166249
🇯🇵Koto-ku, Tokyo, Japan
Matsusaka City Hospital /ID# 166126
🇯🇵Matsusaka-shi MIE, Japan
UZ Leuven /ID# 158752
🇧🇪Leuven, Belgium
Cross Cancer Institute /ID# 159519
🇨🇦Edmonton, Alberta, Canada
Hopital du Sacre Coeur Montreal /ID# 159515
🇨🇦Montreal, Quebec, Canada
Kanagawa Cardiovascular and Respiratory Center /ID# 164374
🇯🇵Yokohama-shi, Kanagawa, Japan
Japanese Red Cross Okayama Hospital /ID# 165156
🇯🇵Okayama-shi, Okayama, Japan
Osaka City General Hospital /ID# 165717
🇯🇵Osaka-shi, Osaka, Japan
Riga East Clinical University /ID# 158714
🇱🇻Riga, Latvia
Hacettepe University Medical Faculty /ID# 159238
🇹🇷Altindağ, Ankara, Turkey
Kanagawa Cancer Center /ID# 165816
🇯🇵Yokohama, Japan
Unidade Local Saude Matosinhos /ID# 158682
🇵🇹Matosinhos, Portugal
Hospital CUF Porto /ID# 158685
🇵🇹Porto, Portugal
Spitalul Judetean de Urgenta A /ID# 160846
🇷🇴Alba, Romania
Taichung Veterans General Hosp /ID# 158866
🇨🇳Taichung City, Taiwan
Isala /ID# 158653
🇳🇱Zwolle, Netherlands
Szpitale Pomorskie Sp. z o.o /ID# 160536
🇵🇱Gdynia, Poland
Centro Hospitalar Lisboa Norte, EPE /ID# 158687
🇵🇹Lisbon, Lisboa, Portugal
Hospital Clinic /ID# 159031
🇪🇸Barcelona, Spain
Semmelweis Egyetem /ID# 161197
🇭🇺Budapest, Hungary
Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA) /ID# 159665
🇧🇷Rio de Janeiro, Brazil
Thomayerova nemocnice /ID# 159061
🇨🇿Prague, Praha 4, Czechia
Southern Medical Day Care Ctr /ID# 158853
🇦🇺Wollongong, New South Wales, Australia
Evangelische Lungenklinik Berl /ID# 159168
🇩🇪Berlin, Germany
Thoraxklinik Heidelberg gGmbH /ID# 159169
🇩🇪Heidelberg, Germany
Chungbuk National University /ID# 159291
🇰🇷Cheongju-si, Korea, Republic of
University of California, Davis Comprehensive Cancer Center /ID# 157001
🇺🇸Sacramento, California, United States
University of Louisville /ID# 155947
🇺🇸Louisville, Kentucky, United States
Klinicki bolnicki centar Sestre milosrdnice /ID# 158811
🇭🇷Zagreb, Grad Zagreb, Croatia
Duplicate_Kanazawa University Hospital /ID# 165129
🇯🇵Kanazawa-shi, Ishikawa, Japan
Sendai Kousei Hospital /ID# 166061
🇯🇵Sendai-shi, Miyagi, Japan
Bobruysk Interdistrict Onco. /ID# 169394
🇧🇾Bobruisk, Belarus
Cliniques universitaires Saint /ID# 158751
🇧🇪Brussels, Belgium
Centre Hosp Intercommunal de Creteil /ID# 162684
🇫🇷Creteil, Val-de-Marne, France
Kurume University Hospital /ID# 164586
🇯🇵Kurume-shi, Fukuoka, Japan
CHU Saint-Pierre /ID# 159521
🇧🇪Bruxelles, Bruxelles-Capitale, Belgium
Metropolitan Hospital /ID# 159162
🇬🇷Athens, Greece
Wakayama Medical University /ID# 166032
🇯🇵Wakayama-shi, Wakayama, Japan
Ziekenhuis St. Jansdal /ID# 158652
🇳🇱Harderwijk, Netherlands
Oncocenter Oncologie Clinica S /ID# 160848
🇷🇴Timisoara, Timis, Romania
N.N. Petrov Research Inst Onc /ID# 159312
🇷🇺St. Petersburg, Russian Federation
National Taiwan University Hospital /ID# 158865
🇨🇳Taipei City, Taipei, Taiwan
Pauls Stradins Clinical /ID# 158713
🇱🇻Riga, Latvia
CHU de Quebec-Universite Laval /ID# 159093
🇨🇦Quebec City, Quebec, Canada
Hopital Haut-Lévêque /ID# 160558
🇫🇷Pessac CEDEX, Gironde, France
Aichi Cancer Center Hospital /ID# 164975
🇯🇵Nagoya-shi, Aichi, Japan
Kyushu University Hospital /ID# 165723
🇯🇵Fukuoka-shi, Fukuoka, Japan
Shizuoka Cancer Center /ID# 166466
🇯🇵Sunto-gun, Shizuoka, Japan
National Cancer Center Hospital /ID# 166768
🇯🇵Chuo-ku, Tokyo, Japan
Centro de Investigación Clinica Chapultepec /ID# 161000
🇲🇽Morelia, Michoacan, Mexico
Kaluga Regional Clinical Oncol /ID# 160179
🇷🇺Kaluga, Russian Federation
Institut za onkologiju i radio /ID# 160058
🇷🇸Belgrade, Serbia
Municipal institution Multifie /ID# 159121
🇺🇦Dnipro, Ukraine
ME Kryviy Rih Oncology Dispensary /ID# 159119
🇺🇦Kryviy RIH, Ukraine
LLC Novaya Klinika /ID# 205539
🇷🇺Pyatigorsk, Stavropol Skiy Kray, Russian Federation
Arkhangelsk clinical oncology /ID# 159309
🇷🇺Arkhangelsk, Russian Federation
Clinical Onco Dispensary /ID# 159307
🇷🇺Omsk, Russian Federation
Smolensk Regional Onc Clin Dis /ID# 159314
🇷🇺Smolensk, Russian Federation
Clinical Center of Nis /ID# 160059
🇷🇸NIS, Nisavski Okrug, Serbia
Volyn Regional Medical Oncology Centre /ID# 159124
🇺🇦Lutsk, Ukraine
Univ Medical Ctr Brackenridge /ID# 156967
🇺🇸Austin, Texas, United States
Cancer Specialists of North Florida - Southpoint /ID# 155828
🇺🇸Jacksonville, Florida, United States
Austin Hospital /ID# 158898
🇦🇺Heidelberg, Victoria, Australia
Juravinski Cancer Clinic /ID# 159514
🇨🇦Hamilton, Ontario, Canada
Cisss Du Bas-Saint-Laurent Hopital Regional de Rimouski /Id# 208931
🇨🇦Rimouski, Quebec, Canada